PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

The paper considers the joint management of rheumatoid arthritis patients needing endoprosthetic replacement of the large joints of the lower extremities by rheumatologists and orthopedic traumatologists.Due to the fact that there are no conventional standards or guidelines for the perioperative man...

Full description

Bibliographic Details
Main Authors:	V. N. Amirdzhanova, M. A. Makarov, E. I. Byalik, S. A. Makarov, M. M. Lipina
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2014-09-01
Series:	Научно-практическая ревматология
Subjects:	rheumatoid arthritis endoprosthetic joint replacement disease-modifying antirheumatic drugs genetically engineered biological agents
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1956

Similar Items

The specific features of diagnosis of rheumatoid arthritis in real clinical practice
by: Elena Andreevna Galushko, et al.
Published: (2011-02-01)

SHOULD DISEASE-MODIFYING THERAPY BE STOPPED IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE ENDOPROSTHETIC JOINT REPLACEMENT?
by: N. A. Savenkova, et al.
Published: (2011-06-01)

Does endoprosthetic replacement of large joints improve quality of life in patients with rheumatoid arthritis?
by: Nadezhda Alekseevna Savenkova, et al.
Published: (2011-02-01)

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations
by: E L Nasonov
Published: (2016-12-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

MODERN VIEWS ON PATHOGENETIC THERAPY OF RHEUMATOID ARTHRITIS
by: D. G. Rekalov, et al.
Published: (2013-12-01)

PERIPROSTHETIC INFECTION AFTER ENDOPROSTHETIC REPLACEMENT OF THE HIP JOINT IN PATIENTS WITH RHEUMATOID DISEASES
by: Vadim Petrovich Pavlov, et al.
Published: (2014-02-01)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020-08-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2016-10-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

Complications after endoprosthetic joint replacement in patients receiving genetically engineered biological agents
by: Elena Yuryevna Pogozheva, et al.
Published: (2012-06-01)

First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study
by: Paula Muilu, et al.
Published: (2020-07-01)

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA
by: T. V. Popkova, et al.
Published: (2016-07-01)

Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity
by: Kichul Shin, et al.
Published: (2020-01-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
by: Seogsong Jeong, et al.
Published: (2022-07-01)

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
by: Kichul Shin, et al.
Published: (2022-09-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study
by: Yusuke Kashiwado, et al.
Published: (2022-06-01)

Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
by: Ivan Padjen, et al.
Published: (2020-12-01)

A Comparison of Demographics, Disease Activity, Disability, and Treatment Among Rheumatoid Arthritis Patients with and without Osteoporosis
by: Abdulkhaliq A, et al.
Published: (2021-09-01)

Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
by: So Hye Nam, et al.
Published: (2022-04-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

The prevention of venous thromboembolism and the risk of postoperative complications in patients with rheumatoid arthritis and osteoarthritis after total hip arthroplasty
by: A. V. Rybnikov, et al.
Published: (2019-01-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)

Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial
by: Shangwen Lei, et al.
Published: (2022-07-01)

The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis
by: Der-Yuan Chen, et al.
Published: (2022-12-01)

THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2018-05-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study
by: Małgorzata Wisłowska
Published: (2022-05-01)

iTRAQ and PRM-Based Proteomic Analysis Provides New Insights into Mechanisms of Response to Triple Therapy in Patients with Rheumatoid Arthritis
by: Chen J, et al.
Published: (2021-12-01)

Rheumatoid arthritis – medication dosage in chronic kidney disease
by: Kinga Maria Tyczyńska, et al.
Published: (2024-01-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2015-09-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2015-10-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2016-12-01)

FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES
by: A. A. Abramkin, et al.
Published: (2018-09-01)

Long-term results of elbow synovectomy and debridement in rheumatoid arthritis
by: Anastasia Aleksandrovna Roskidailo, et al.
Published: (2011-12-01)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
by: van Heuckelum M, et al.
Published: (2019-07-01)